US2021268002A1PendingUtilityA1

Androgen composition for treating an opthalmic condition

75
Assignee: ALLERGAN INCPriority: Jan 26, 2011Filed: Jan 12, 2021Published: Sep 2, 2021
Est. expiryJan 26, 2031(~4.5 yrs left)· nominal 20-yr term from priority
Inventors:John T. TrogdenAdnan K. SalamehChetan P. PujaraAnuradha V. GoreJaya Giyanani
A61K 31/569A61K 31/568A61K 31/5685A61P 29/00A61P 27/02A61K 31/20A61K 47/40A61K 9/107A61K 45/06A61K 9/00A61K 47/06A61K 47/32A61K 9/0048A61K 47/10A61P 5/26A61P 31/00A61K 47/44A61K 47/02A61K 36/47A61P 23/00A61K 47/26A61P 21/02
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . An ophthalmic emulsion comprising testosterone in an amount of about 0.03 w/w % and castor oil in an amount of about 0.25 w/w %, wherein the emulsion is suitable for topical administration to an eye. 
     
     
         2 . The emulsion of  claim 1 , wherein the emulsion further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof. 
     
     
         2 . The emulsion of  claim 1 , further comprising an agent selected from the group consisting of an anti-inflammatory, antimicrobial, analgesic, anesthetic, lubricating agent, and a combination thereof. 
     
     
         3 . The emulsion of  claim 1 , further comprising a solubility enhancing agent. 
     
     
         4 . A method for treating an ocular condition resulting from an androgen deficiency comprising administering the ophthalmic emulsion of  claim 1  to a patient in need thereof, wherein at least one symptom of the ocular condition is alleviated. 
     
     
         5 . The method of  claim 4 , wherein the ocular condition is blepharitis. 
     
     
         6 . The method of  claim 4 , wherein the ophthalmic emulsion comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof. 
     
     
         7 . The method of  claim 4 , wherein symptoms associated with the ocular condition are reduced. 
     
     
         8 . The method of  claim 4 , wherein symptoms associated with the ocular condition are eliminated. 
     
     
         9 . The method of  claim 4 , wherein the administration is repeated until one or more symptoms of the ocular condition are reduced. 
     
     
         10 . The method of  claim 4 , wherein the administration is repeated until one or more symptoms of the ocular condition are eliminated. 
     
     
         11 . The method of  claim 4 , wherein the ophthalmic emulsion is administered to the eye, upper lid, lower lid, or a combination thereof. 
     
     
         12 . An ophthalmic emulsion comprising testosterone in an amount of about 0.1 w/w % and castor oil in an amount of about 0.25 w/w % wherein the emulsion is suitable for topical administration to an eye. 
     
     
         13 . The emulsion of  claim 12 , wherein the emulsion further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof. 
     
     
         14 . The emulsion of  claim 12 , further comprising a solubility enhancing agent. 
     
     
         15 . A method for treating an ocular condition resulting from an androgen deficiency comprising administering the ophthalmic emulsion of  claim 12  to a patient in need thereof, wherein at least one symptom of the ocular condition is alleviated. 
     
     
         16 . The method of  claim 15 , wherein the ocular condition is blepharitis. 
     
     
         17 . The method of  claim 15 , wherein symptoms associated with the ocular condition are reduced. 
     
     
         18 . The method of  claim 15 , wherein symptoms associated with the ocular condition are eliminated. 
     
     
         19 . The method of  claim 15 , wherein the ophthalmic emulsion is administered to the eye, upper lid, lower lid, or a combination thereof. 
     
     
         20 . An ophthalmic emulsion comprising testosterone in an amount of about 0.3 w/w % and castor oil in an amount of about 0.25 w/w %, wherein the emulsion is suitable for topical administration to an eye. 
     
     
         21 . The emulsion of  claim 20 , wherein the emulsion further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof. 
     
     
         22 . The emulsion of  claim 20 , further comprising a solubility enhancing agent. 
     
     
         23 . A method for treating an ocular condition resulting from an androgen deficiency comprising administering the ophthalmic emulsion of  claim 20  to a patient in need thereof, wherein at least one symptom of the ocular condition is alleviated. 
     
     
         24 . The method of  claim 23 , wherein the ocular condition is blepharitis. 
     
     
         25 . The method of  claim 23 , wherein symptoms associated with the ocular condition are reduced. 
     
     
         26 . The method of  claim 3 , wherein symptoms associated with the ocular condition are eliminated. 
     
     
         27 . The method of  claim 23 , wherein the ophthalmic emulsion is administered to the eye, upper lid, lower lid, or a combination thereof.

Join the waitlist — get patent alerts

Track US2021268002A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.